This document discusses Enhanced Recovery After Surgery (ERAS) for gastric cancer (ERAS-GC). It outlines the components of ERAS-GC, which include general guidelines like early mobilization and feeding as well as procedure-specific guidelines. The document then describes how ERAS-GC was introduced at the author's hospital, including the protocol and discharge criteria. Finally, it presents two case examples comparing outcomes for patients who received ERAS-GC versus traditional care, finding improved short-term outcomes like faster recovery of bowel function and shorter hospital stay with ERAS-GC.
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative OutcomesWellbe
Speaker: Francesco Carli, MD, MPhil, senior staff anesthesiologist at the McGill University Health Centre
Cost: Complimentary, sponsored by Wellbe
There is strong evidence that many of aspects of surgical care have little evidence, and therefore the Enhanced Recovery After Surgery (ERAS) program has been set up to accelerate the recovery process and decrease the rate of postoperative complications. There is an opportunity to improve outcomes by using team approach and revision of the standard procedures.
Learn about:
– The elements of ERAS protocols
– How to structure the Team approach
– The role of the patient in ERAS
– How to perform an audit of your program
About the Speaker:
Francesco Carli, MD, MPhil, is Professor of Anesthesia at McGill University and Associate Professor in the School of Dietetics and Human Nutrition at McGill University and a senior staff anesthesiologist at the McGill University Health Centre. He is currently an Elected Member of the American Academy of Anesthesia and a Board Member of the Enhanced Recovery After Surgery (ERAS) Society. Dr. Carli completed his medical training and anesthesia training in Turin, Italy, Paris, France, and London, England. He completed a Master’s Degree in surgical metabolism at the University of London, England.
His research interests are: metabolic changes associated with surgery and the impact of perioperative interventions (regional analgesia, nutrition, hormones, exercise) on postoperative recovery; evaluation of functional outcome measures during the surgical recovery process; prehabilitation of surgical patients. He is the author of over 250 peer-review scientific articles and has been a recipient of over 50 peer and non peer-review grants.
The ERAS protocol was developed in 2001 to improve surgical recovery through evidence-based practices. It utilizes a multidisciplinary team and multimodal interventions including preoperative education and carbohydrate loading, intraoperative fluid management and opioid-sparing techniques, and postoperative early nutrition, ambulation and defined discharge criteria. Implementation of ERAS has been shown to reduce length of hospital stay by 35-40% and complications rates while lowering healthcare costs. While initially developed for colorectal surgery, ERAS has been applied to other specialties and demonstrated benefits but faces barriers to widespread adoption including resistance to changing traditional practices.
This document provides guidelines for perioperative care in elective colorectal surgery as part of an Enhanced Recovery After Surgery (ERAS) protocol. It makes recommendations for several preadmission items including preadmission counselling and education, preoperative optimization of medical conditions, prehabilitation, preoperative nutrition, management of anemia, and prevention of postoperative nausea and vomiting. The recommendations are based on reviews of the available evidence and are intended to reduce complications and facilitate early recovery after colorectal surgery.
Neoadjuvant therapy, including chemotherapy and chemoradiotherapy, is being investigated for the treatment of esophageal cancer. While some studies have shown improved survival rates with neoadjuvant therapy compared to surgery alone, the evidence from clinical trials remains conflicting. Achieving a complete pathological response after neoadjuvant therapy is associated with significantly improved long-term survival. Further research is still needed to determine the optimal neoadjuvant approaches and to improve outcomes by reducing distant metastases.
Enhanced Recovery After Surgery (ERAS) aims to optimize patient outcomes and reduce costs through a multimodal perioperative care approach. Traditionally, patients followed principles like prolonged preoperative fasting, use of nasogastric tubes, and long periods of bed rest after surgery. ERAS instead focuses on evidence-based best practices like early mobilization, regional anesthesia, and maintaining normothermia and fluid balance. By avoiding unnecessary dogmas and optimizing the patient's health before and after surgery through a team-based approach, ERAS can provide benefits like shorter hospital stays, less pain and complications, and faster recovery.
This document provides an overview of cholangiocarcinoma, a rare and deadly form of cancer. It discusses risk factors and increasing incidence rates. For localized disease, surgical resection is standard but outcomes remain poor. For advanced disease, gemcitabine-based chemotherapy is the standard first-line treatment based on results from the ABC-02 trial showing improved survival with gemcitabine and cisplatin. Retrospective data on second-line therapies and combination of pazopanib and trametinib show some benefit. Adding radiation therapy may also improve outcomes based on another retrospective review. Next generation sequencing is helping identify molecular alterations to guide targeted therapy trials. Ongoing clinical trials at MD Anderson include testing new
The document discusses the Enhanced Recovery After Surgery (ERAS) protocol. ERAS aims to optimize patient care and recovery through a multidisciplinary, evidence-based approach. It challenges traditional practices like prolonged preoperative fasting and use of drains. The ERAS protocol incorporates recommendations across the preoperative, intraoperative and postoperative periods. This includes carbohydrate loading, minimal fasting, optimized fluid management, multimodal analgesia, early nutrition and mobilization to reduce complications and length of stay while improving outcomes.
This document discusses Enhanced Recovery Programs (ERPs), which aim to reduce stress response to surgery and accelerate recovery through a multimodal perioperative care pathway. Key elements of ERPs include preoperative counseling and carbohydrate loading, avoiding mechanical bowel preparation and nasogastric tubes, use of thoracic epidurals, short-acting anesthetics, goal-directed fluid therapy, normothermia, short incisions or laparoscopy, early oral intake and mobilization, and clear discharge criteria focused on independence rather than length of stay. Strict adherence to an ERP can reduce typical hospital stays for major colorectal surgery from 7-14 days to 2-3 days. ERPs require a multidisciplinary team
Using Enhanced Recovery After Surgery (ERAS) to Enhance Postoperative OutcomesWellbe
Speaker: Francesco Carli, MD, MPhil, senior staff anesthesiologist at the McGill University Health Centre
Cost: Complimentary, sponsored by Wellbe
There is strong evidence that many of aspects of surgical care have little evidence, and therefore the Enhanced Recovery After Surgery (ERAS) program has been set up to accelerate the recovery process and decrease the rate of postoperative complications. There is an opportunity to improve outcomes by using team approach and revision of the standard procedures.
Learn about:
– The elements of ERAS protocols
– How to structure the Team approach
– The role of the patient in ERAS
– How to perform an audit of your program
About the Speaker:
Francesco Carli, MD, MPhil, is Professor of Anesthesia at McGill University and Associate Professor in the School of Dietetics and Human Nutrition at McGill University and a senior staff anesthesiologist at the McGill University Health Centre. He is currently an Elected Member of the American Academy of Anesthesia and a Board Member of the Enhanced Recovery After Surgery (ERAS) Society. Dr. Carli completed his medical training and anesthesia training in Turin, Italy, Paris, France, and London, England. He completed a Master’s Degree in surgical metabolism at the University of London, England.
His research interests are: metabolic changes associated with surgery and the impact of perioperative interventions (regional analgesia, nutrition, hormones, exercise) on postoperative recovery; evaluation of functional outcome measures during the surgical recovery process; prehabilitation of surgical patients. He is the author of over 250 peer-review scientific articles and has been a recipient of over 50 peer and non peer-review grants.
The ERAS protocol was developed in 2001 to improve surgical recovery through evidence-based practices. It utilizes a multidisciplinary team and multimodal interventions including preoperative education and carbohydrate loading, intraoperative fluid management and opioid-sparing techniques, and postoperative early nutrition, ambulation and defined discharge criteria. Implementation of ERAS has been shown to reduce length of hospital stay by 35-40% and complications rates while lowering healthcare costs. While initially developed for colorectal surgery, ERAS has been applied to other specialties and demonstrated benefits but faces barriers to widespread adoption including resistance to changing traditional practices.
This document provides guidelines for perioperative care in elective colorectal surgery as part of an Enhanced Recovery After Surgery (ERAS) protocol. It makes recommendations for several preadmission items including preadmission counselling and education, preoperative optimization of medical conditions, prehabilitation, preoperative nutrition, management of anemia, and prevention of postoperative nausea and vomiting. The recommendations are based on reviews of the available evidence and are intended to reduce complications and facilitate early recovery after colorectal surgery.
Neoadjuvant therapy, including chemotherapy and chemoradiotherapy, is being investigated for the treatment of esophageal cancer. While some studies have shown improved survival rates with neoadjuvant therapy compared to surgery alone, the evidence from clinical trials remains conflicting. Achieving a complete pathological response after neoadjuvant therapy is associated with significantly improved long-term survival. Further research is still needed to determine the optimal neoadjuvant approaches and to improve outcomes by reducing distant metastases.
Enhanced Recovery After Surgery (ERAS) aims to optimize patient outcomes and reduce costs through a multimodal perioperative care approach. Traditionally, patients followed principles like prolonged preoperative fasting, use of nasogastric tubes, and long periods of bed rest after surgery. ERAS instead focuses on evidence-based best practices like early mobilization, regional anesthesia, and maintaining normothermia and fluid balance. By avoiding unnecessary dogmas and optimizing the patient's health before and after surgery through a team-based approach, ERAS can provide benefits like shorter hospital stays, less pain and complications, and faster recovery.
This document provides an overview of cholangiocarcinoma, a rare and deadly form of cancer. It discusses risk factors and increasing incidence rates. For localized disease, surgical resection is standard but outcomes remain poor. For advanced disease, gemcitabine-based chemotherapy is the standard first-line treatment based on results from the ABC-02 trial showing improved survival with gemcitabine and cisplatin. Retrospective data on second-line therapies and combination of pazopanib and trametinib show some benefit. Adding radiation therapy may also improve outcomes based on another retrospective review. Next generation sequencing is helping identify molecular alterations to guide targeted therapy trials. Ongoing clinical trials at MD Anderson include testing new
The document discusses the Enhanced Recovery After Surgery (ERAS) protocol. ERAS aims to optimize patient care and recovery through a multidisciplinary, evidence-based approach. It challenges traditional practices like prolonged preoperative fasting and use of drains. The ERAS protocol incorporates recommendations across the preoperative, intraoperative and postoperative periods. This includes carbohydrate loading, minimal fasting, optimized fluid management, multimodal analgesia, early nutrition and mobilization to reduce complications and length of stay while improving outcomes.
This document discusses Enhanced Recovery Programs (ERPs), which aim to reduce stress response to surgery and accelerate recovery through a multimodal perioperative care pathway. Key elements of ERPs include preoperative counseling and carbohydrate loading, avoiding mechanical bowel preparation and nasogastric tubes, use of thoracic epidurals, short-acting anesthetics, goal-directed fluid therapy, normothermia, short incisions or laparoscopy, early oral intake and mobilization, and clear discharge criteria focused on independence rather than length of stay. Strict adherence to an ERP can reduce typical hospital stays for major colorectal surgery from 7-14 days to 2-3 days. ERPs require a multidisciplinary team
ERAS (Enhanced Recovery After Surgery) is a collection of evidence-based practices designed to improve recovery after major surgery. The goals are to reduce surgical stress, maintain normal physiologic function, and enhance early mobilization. ERAS emphasizes preoperative education, minimizing fasting times, multimodal pain control, early feeding and mobilization to reduce length of stay, complications, and costs while improving patient satisfaction. It was first developed in the 1990s and involves protocols tailored for specific surgeries like gynecologic procedures.
The document discusses Enhanced Recovery After Surgery (ERAS) protocols. It describes how ERAS aims to reduce surgical stress on patients through multimodal perioperative care, facilitating early recovery. This includes optimizations in pre-, intra-, and postoperative care such as shortened fasting times, carbohydrate loading, minimized fluid administration, and early mobilization. The document provides examples of procedures that can be done as day surgeries and details the key elements of ERAS protocols.
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaDr.Bhavin Vadodariya
This randomized controlled trial compared neoadjuvant chemoradiotherapy followed by surgery to upfront surgery followed by adjuvant therapy for patients with borderline resectable pancreatic cancer. It found that the neoadjuvant treatment approach significantly improved 2-year survival rates compared to upfront surgery. Specifically, the 2-year survival rate was 40.7% for the neoadjuvant group versus 26.1% for the upfront surgery group. The neoadjuvant approach also resulted in a higher R0 resection rate and median overall survival of 21 months compared to 12 months for upfront surgery. However, both approaches had similar recurrence rates, with most recurrences being systemic.
HIPEC, or hyperthermic intraperitoneal chemotherapy, is a treatment for advanced cancers that have spread to the peritoneum. It involves delivering heated chemotherapy directly into the peritoneal cavity during cytoreductive surgery to remove any visible tumors. HIPEC aims to treat any remaining microscopic disease. Heating the chemotherapy to 41-42°C allows it to penetrate deeper tissues and more effectively kill cancer cells compared to normal intraperitoneal or intravenous chemotherapy alone. While HIPEC is effective, it is also associated with increased risks of complications due to the combined effects of surgery, chemotherapy, and localized hyperthermia.
This document discusses the role of chemotherapy in colon cancer. It begins with an introduction on the epidemiology and causes of colon cancer. It then covers staging of colon cancer using the AJCC TNM system and discusses prognostic factors. It describes the rationale for and trials supporting adjuvant chemotherapy for stages II and III colon cancer. It provides details on different chemotherapy drugs used for colon cancer including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan. It discusses various 5-FU regimens including Mayo, Roswell Park, bolus vs continuous infusion vs intermittent infusion schedules.
This document discusses the treatment of ovarian carcinoma. It begins with an overview of the epidemiology, patterns of spread, symptoms, diagnostic workup and surgical staging of the disease. It then describes the histopathological classification and various chemotherapy regimens used as adjuvant treatment, including platinum-based drugs like cisplatin and carboplatin, and taxanes like paclitaxel. The standard first-line regimen for early-stage high-risk ovarian cancer is 6 cycles of paclitaxel and carboplatin given every 3 weeks.
This document discusses day case surgery (DCS). It begins with an introduction on the prevalence of DCS internationally. It then covers the definition, history, merits and demerits of DCS. Key aspects of setting up and running a successful DCS unit are described, including space requirements, staffing, suitable procedures, pre-op preparation, and discharge criteria. The document concludes with a discussion on audit and special considerations for DCS in children and emergencies.
This document discusses several landmark trials comparing different treatment approaches for esophageal cancer. The CALGB 9781 trial compared trimodality therapy (chemotherapy, radiation therapy, and surgery) to surgery alone and found improved overall survival and progression-free survival with trimodality therapy. Median overall survival was 4.48 years with trimodality therapy versus 1.79 years with surgery alone. The trial was closed early due to poor accrual, resulting in a small sample size.
Advances in management of castration resistant prostate cancerAlok Gupta
Given this patient's advanced age and comorbidities, I would recommend abiraterone acetate as the second line treatment option post enzalutamide progression. Abiraterone has shown survival benefit with good tolerability in older patients with comorbidities in the COU-AA-301 trial. Cabazitaxel could be considered but may have higher toxicity risks in this patient. Close monitoring would be needed.
1) The document discusses artery first approaches to pancreatoduodenectomy (PD), specifically the superior mesenteric artery (SMA) first approach.
2) Meta-analysis data suggests the SMA first approach may reduce blood loss, operating time, pancreatic fistula rates and morbidity compared to standard PD, while increasing R0 resection rates.
3) However, there is no definitive evidence yet that the SMA first approach improves long-term survival outcomes. The main role of the approach is to facilitate early assessment of resectability, especially for borderline resectable pancreatic cancers.
Enhanced Recovery after Surgery its relevance - Evidence BasedDeep Goel
Enhanced recovery programs are evidence-based protocols designed to standardize medical care, improve outcomes, and lower health care costs. These protocols include evidence-based techniques to minimize surgical trauma and postoperative pain, reduce complications, improve outcomes, and decrease hospital length of stay, while expediting recovery following elective procedures.Protocols have been developed for colorectal surgery patients to reduce physiological stress and postoperative organ dysfunction through optimization of perioperative care and recovery
Management of prostate cancer involves assessing risk levels based on PSA, Gleason score, and percentage of positive biopsy cores. Treatment options include active surveillance for low risk prostate cancer with potential delayed treatment if cancer progresses. Radical prostatectomy is the gold standard for localized prostate cancer and provides the possibility of cure with minimal side effects when performed by an experienced surgeon. While providing excellent cancer control, radical prostatectomy carries risks of erectile dysfunction and urinary incontinence.
This document discusses metastatic colorectal liver cancer. It outlines risk factors, evaluation, and treatment options including surgery, chemotherapy, local tumor ablation, and radiotherapy. Surgery offers the best chance of survival if metastases are resectable, with 5-year survival rates of 24-58% for resection. Neoadjuvant chemotherapy can help make previously unresectable tumors operable. Local ablation techniques are alternatives for tumors that cannot be surgically removed.
1. Resection offers the only chance of cure for pancreatic cancer, but adjuvant therapy after surgery may improve outcomes. Studies have shown benefits from chemoradiation over chemotherapy alone.
2. For borderline resectable or locally advanced unresectable disease, neoadjuvant therapy or chemoradiation may help make initially unresectable tumors operable or improve survival compared to chemotherapy alone.
3. Intensity modulated radiation therapy (IMRT) allows safer dose escalation and better sparing of nearby organs compared to 3D conformal radiation, potentially improving local control and survival. Proper motion management and image guidance are needed to fully realize the benefits of IMRT.
This document discusses chemotherapy trials and regimens for colon cancer. It summarizes several landmark trials that established the benefit of 5-FU-based adjuvant chemotherapy for stage III colon cancer. The MOSAIC, NSABP C-07 and NO16968 trials showed that adding oxaliplatin to 5-FU improves disease-free survival for stage III disease. For stage II, the benefit of oxaliplatin is unclear. The document also discusses staging, risk factors, treatment guidelines, neoadjuvant therapy and radiation therapy options for colon cancer.
1) Cancers of the gastroesophageal junction are either adenocarcinomas or squamous cell carcinomas. Adenocarcinomas arise from Barrett's esophagus, an abnormal change in the esophageal lining, while squamous cell carcinomas are preceded by dysplasia.
2) Endoscopic ultrasound and diagnostic laparoscopy are used to accurately stage gastroesophageal junction cancers before deciding if the cancer can be surgically removed.
3) The type of surgery performed depends on the location and stage of the cancer, with tumors closer to the stomach treated more like gastric cancers and those higher up treated like esophageal cancers. The goal is to remove the cancer and nearby lymph nodes.
Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface MalignanciesMary Ondinee Manalo Igot
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is emerging as a new standard treatment for peritoneal surface malignancies. Traditionally, peritoneal carcinomatosis was considered incurable and treated only with palliative chemotherapy. However, CRS-HIPEC aims to remove all visible tumor deposits surgically and then uses heated chemotherapy in the abdominal cavity to target any remaining microscopic disease. Studies show CRS-HIPEC provides significantly longer survival times compared to intravenous chemotherapy alone, with median overall survivals of 16-36 months. Experts indicate CRS-HIPEC should now be considered the standard of care for select patients with peritoneal metastases from conditions like ovarian
Fast-track or enhanced recovery after surgery (ERAS) protocols aim to reduce the stress response to surgery and speed recovery. This document outlines ERAS protocols for several types of surgeries including colorectal, bariatric, liver, breast and gallbladder surgeries. The protocols emphasize preoperative counseling and nutrition, minimal invasive surgery when possible, multimodal pain control, early feeding and mobilization to reduce hospital length of stay and complications compared to traditional care.
Spanish Multi-Center Fast-Track Group - Protocol and Preliminary Resultsfast.track
The document describes a multi-center study protocol and preliminary results for introducing an enhanced recovery program in colorectal surgery. The protocol aims to optimize pre-operative, intra-operative, and post-operative patient care and treatment to reduce morbidity, accelerate recovery, shorten hospital stays, and reduce costs. Preliminary retrospective results from one hospital show average length of stay was 12.1 days with 34.8% of patients experiencing complications. A prospective multi-center study will evaluate outcomes including success of the program, patient satisfaction, complications, mortality, re-operations, and readmissions.
ERAS (Enhanced Recovery After Surgery) is a collection of evidence-based practices designed to improve recovery after major surgery. The goals are to reduce surgical stress, maintain normal physiologic function, and enhance early mobilization. ERAS emphasizes preoperative education, minimizing fasting times, multimodal pain control, early feeding and mobilization to reduce length of stay, complications, and costs while improving patient satisfaction. It was first developed in the 1990s and involves protocols tailored for specific surgeries like gynecologic procedures.
The document discusses Enhanced Recovery After Surgery (ERAS) protocols. It describes how ERAS aims to reduce surgical stress on patients through multimodal perioperative care, facilitating early recovery. This includes optimizations in pre-, intra-, and postoperative care such as shortened fasting times, carbohydrate loading, minimized fluid administration, and early mobilization. The document provides examples of procedures that can be done as day surgeries and details the key elements of ERAS protocols.
Neoadjuvant Chemoradiation in Borderline resectable pancreatic adenocarcinomaDr.Bhavin Vadodariya
This randomized controlled trial compared neoadjuvant chemoradiotherapy followed by surgery to upfront surgery followed by adjuvant therapy for patients with borderline resectable pancreatic cancer. It found that the neoadjuvant treatment approach significantly improved 2-year survival rates compared to upfront surgery. Specifically, the 2-year survival rate was 40.7% for the neoadjuvant group versus 26.1% for the upfront surgery group. The neoadjuvant approach also resulted in a higher R0 resection rate and median overall survival of 21 months compared to 12 months for upfront surgery. However, both approaches had similar recurrence rates, with most recurrences being systemic.
HIPEC, or hyperthermic intraperitoneal chemotherapy, is a treatment for advanced cancers that have spread to the peritoneum. It involves delivering heated chemotherapy directly into the peritoneal cavity during cytoreductive surgery to remove any visible tumors. HIPEC aims to treat any remaining microscopic disease. Heating the chemotherapy to 41-42°C allows it to penetrate deeper tissues and more effectively kill cancer cells compared to normal intraperitoneal or intravenous chemotherapy alone. While HIPEC is effective, it is also associated with increased risks of complications due to the combined effects of surgery, chemotherapy, and localized hyperthermia.
This document discusses the role of chemotherapy in colon cancer. It begins with an introduction on the epidemiology and causes of colon cancer. It then covers staging of colon cancer using the AJCC TNM system and discusses prognostic factors. It describes the rationale for and trials supporting adjuvant chemotherapy for stages II and III colon cancer. It provides details on different chemotherapy drugs used for colon cancer including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan. It discusses various 5-FU regimens including Mayo, Roswell Park, bolus vs continuous infusion vs intermittent infusion schedules.
This document discusses the treatment of ovarian carcinoma. It begins with an overview of the epidemiology, patterns of spread, symptoms, diagnostic workup and surgical staging of the disease. It then describes the histopathological classification and various chemotherapy regimens used as adjuvant treatment, including platinum-based drugs like cisplatin and carboplatin, and taxanes like paclitaxel. The standard first-line regimen for early-stage high-risk ovarian cancer is 6 cycles of paclitaxel and carboplatin given every 3 weeks.
This document discusses day case surgery (DCS). It begins with an introduction on the prevalence of DCS internationally. It then covers the definition, history, merits and demerits of DCS. Key aspects of setting up and running a successful DCS unit are described, including space requirements, staffing, suitable procedures, pre-op preparation, and discharge criteria. The document concludes with a discussion on audit and special considerations for DCS in children and emergencies.
This document discusses several landmark trials comparing different treatment approaches for esophageal cancer. The CALGB 9781 trial compared trimodality therapy (chemotherapy, radiation therapy, and surgery) to surgery alone and found improved overall survival and progression-free survival with trimodality therapy. Median overall survival was 4.48 years with trimodality therapy versus 1.79 years with surgery alone. The trial was closed early due to poor accrual, resulting in a small sample size.
Advances in management of castration resistant prostate cancerAlok Gupta
Given this patient's advanced age and comorbidities, I would recommend abiraterone acetate as the second line treatment option post enzalutamide progression. Abiraterone has shown survival benefit with good tolerability in older patients with comorbidities in the COU-AA-301 trial. Cabazitaxel could be considered but may have higher toxicity risks in this patient. Close monitoring would be needed.
1) The document discusses artery first approaches to pancreatoduodenectomy (PD), specifically the superior mesenteric artery (SMA) first approach.
2) Meta-analysis data suggests the SMA first approach may reduce blood loss, operating time, pancreatic fistula rates and morbidity compared to standard PD, while increasing R0 resection rates.
3) However, there is no definitive evidence yet that the SMA first approach improves long-term survival outcomes. The main role of the approach is to facilitate early assessment of resectability, especially for borderline resectable pancreatic cancers.
Enhanced Recovery after Surgery its relevance - Evidence BasedDeep Goel
Enhanced recovery programs are evidence-based protocols designed to standardize medical care, improve outcomes, and lower health care costs. These protocols include evidence-based techniques to minimize surgical trauma and postoperative pain, reduce complications, improve outcomes, and decrease hospital length of stay, while expediting recovery following elective procedures.Protocols have been developed for colorectal surgery patients to reduce physiological stress and postoperative organ dysfunction through optimization of perioperative care and recovery
Management of prostate cancer involves assessing risk levels based on PSA, Gleason score, and percentage of positive biopsy cores. Treatment options include active surveillance for low risk prostate cancer with potential delayed treatment if cancer progresses. Radical prostatectomy is the gold standard for localized prostate cancer and provides the possibility of cure with minimal side effects when performed by an experienced surgeon. While providing excellent cancer control, radical prostatectomy carries risks of erectile dysfunction and urinary incontinence.
This document discusses metastatic colorectal liver cancer. It outlines risk factors, evaluation, and treatment options including surgery, chemotherapy, local tumor ablation, and radiotherapy. Surgery offers the best chance of survival if metastases are resectable, with 5-year survival rates of 24-58% for resection. Neoadjuvant chemotherapy can help make previously unresectable tumors operable. Local ablation techniques are alternatives for tumors that cannot be surgically removed.
1. Resection offers the only chance of cure for pancreatic cancer, but adjuvant therapy after surgery may improve outcomes. Studies have shown benefits from chemoradiation over chemotherapy alone.
2. For borderline resectable or locally advanced unresectable disease, neoadjuvant therapy or chemoradiation may help make initially unresectable tumors operable or improve survival compared to chemotherapy alone.
3. Intensity modulated radiation therapy (IMRT) allows safer dose escalation and better sparing of nearby organs compared to 3D conformal radiation, potentially improving local control and survival. Proper motion management and image guidance are needed to fully realize the benefits of IMRT.
This document discusses chemotherapy trials and regimens for colon cancer. It summarizes several landmark trials that established the benefit of 5-FU-based adjuvant chemotherapy for stage III colon cancer. The MOSAIC, NSABP C-07 and NO16968 trials showed that adding oxaliplatin to 5-FU improves disease-free survival for stage III disease. For stage II, the benefit of oxaliplatin is unclear. The document also discusses staging, risk factors, treatment guidelines, neoadjuvant therapy and radiation therapy options for colon cancer.
1) Cancers of the gastroesophageal junction are either adenocarcinomas or squamous cell carcinomas. Adenocarcinomas arise from Barrett's esophagus, an abnormal change in the esophageal lining, while squamous cell carcinomas are preceded by dysplasia.
2) Endoscopic ultrasound and diagnostic laparoscopy are used to accurately stage gastroesophageal junction cancers before deciding if the cancer can be surgically removed.
3) The type of surgery performed depends on the location and stage of the cancer, with tumors closer to the stomach treated more like gastric cancers and those higher up treated like esophageal cancers. The goal is to remove the cancer and nearby lymph nodes.
Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface MalignanciesMary Ondinee Manalo Igot
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is emerging as a new standard treatment for peritoneal surface malignancies. Traditionally, peritoneal carcinomatosis was considered incurable and treated only with palliative chemotherapy. However, CRS-HIPEC aims to remove all visible tumor deposits surgically and then uses heated chemotherapy in the abdominal cavity to target any remaining microscopic disease. Studies show CRS-HIPEC provides significantly longer survival times compared to intravenous chemotherapy alone, with median overall survivals of 16-36 months. Experts indicate CRS-HIPEC should now be considered the standard of care for select patients with peritoneal metastases from conditions like ovarian
Fast-track or enhanced recovery after surgery (ERAS) protocols aim to reduce the stress response to surgery and speed recovery. This document outlines ERAS protocols for several types of surgeries including colorectal, bariatric, liver, breast and gallbladder surgeries. The protocols emphasize preoperative counseling and nutrition, minimal invasive surgery when possible, multimodal pain control, early feeding and mobilization to reduce hospital length of stay and complications compared to traditional care.
Spanish Multi-Center Fast-Track Group - Protocol and Preliminary Resultsfast.track
The document describes a multi-center study protocol and preliminary results for introducing an enhanced recovery program in colorectal surgery. The protocol aims to optimize pre-operative, intra-operative, and post-operative patient care and treatment to reduce morbidity, accelerate recovery, shorten hospital stays, and reduce costs. Preliminary retrospective results from one hospital show average length of stay was 12.1 days with 34.8% of patients experiencing complications. A prospective multi-center study will evaluate outcomes including success of the program, patient satisfaction, complications, mortality, re-operations, and readmissions.
Peritonectomy is a surgical technique used to treat advanced ovarian cancer that aims to remove all visible tumor from the peritoneal cavity. A study was conducted on peritonectomies performed at the Queensland Centre for Gynaecological Cancer to evaluate the safety and outcomes. The results showed that peritonectomy can debulk tumor down to less than 2cm in size, with smaller residuals associated with better survival rates. However, going from 2cm or less to no visible tumor takes significantly more time and expertise. Patient selection remains a challenge, but modified peritonectomy appears to be a viable option for some advanced ovarian and primary peritoneal cancer cases. Training future surgeons in these complex procedures is important to improving patient outcomes.
1) Gastric cancer surgery can lead to nutritional deficiencies due to loss of stomach and changes to small bowel anatomy. Timely nutritional intervention is important to prevent issues like weight loss and micronutrient deficiencies.
2) Screening patients preoperatively for malnutrition is crucial, as up to 65% of patients may be at nutritional risk. Various screening tools evaluate factors like albumin, weight loss, and muscle mass. Nutritional support for 7-14 days preoperatively can reduce complications.
3) Postoperative nutritional goals include early oral feeding, adequate protein intake, and preventing deficiencies like anemia. Monitoring for deficiencies is important long-term, as nutritional recovery may take up to a year after surgery.
This document discusses weight regain after bariatric surgery and options for revisional surgery. It notes that 50% of patients regain some weight within 2 years of bariatric surgery. Evaluation of weight regain involves assessing patient factors like diet, lifestyle, and medical issues. Revisional surgery depends on the primary procedure and patient characteristics. Options presented include pouch resizing, band adjustment or removal, converting to a different procedure like sleeve gastrectomy or Roux-en-Y gastric bypass. While revisional surgery can provide further weight loss, risks are generally higher than primary procedures and long-term outcomes require more study. Careful patient evaluation and multidisciplinary support are important.
Sugery for chronic pancreatitis.dr quiyumMD Quiyumm
Surgery can provide effective pain relief and improve quality of life for patients with chronic pancreatitis (CP). Common indications for surgery include intractable pain, complications like biliary or duodenal obstruction, and pancreatic head masses that are difficult to differentiate from cancer. Surgical options range from drainage procedures that preserve pancreatic tissue to resection procedures like pancreaticoduodenectomy. While resection can address pain and complications, drainage procedures better preserve endocrine and exocrine function but often lead to recurrent pain. Overall, surgery improves pain control and quality of life for appropriately selected CP patients.
This document outlines a multi-center study protocol for introducing an enhanced recovery program for colorectal surgery. The protocol aims to optimize perioperative care to reduce morbidity, improve recovery, decrease hospital stay and costs. Key elements of the protocol include preoperative nutrition supplementation, avoidance of bowel preparation, use of carbohydrate drinks before surgery, epidural anesthesia, early mobilization and oral intake. Preliminary retrospective results from 182 patients show a postoperative complication rate of 24.82% and average length of stay of 12.1 days. Prospective results from 64 patients show a complication rate of 14.52% and average length of stay of 5.43 days.
A prospective randomized controlled trial assessing the efficacy of omentopex...Ricky Costa
This study aimed to assess whether attaching the omentum (fatty tissue) to the stomach during laparoscopic sleeve gastrectomy (LSG) surgery could help reduce post-operative gastrointestinal (GI) symptoms like nausea and vomiting. The study involved 60 patients undergoing LSG who were randomly assigned to either have LSG alone or LSG with omentopexy. Patients completed surveys assessing GI symptoms at several time points after surgery. The study found that attaching the omentum did not significantly reduce post-operative GI symptoms or food intolerance compared to LSG alone. Patients with omentopexy did require more anti-nausea medication initially but had no difference in other outcomes. The study concludes that
How To Safely Implement A Fast Track Programensteve
The document discusses how to safely implement a fast track recovery program in a hospital. It outlines key steps such as getting agreement from different hospital disciplines on evidence-based fast track interventions, educating staff, regularly reviewing implementation, and measuring outcomes like length of stay, readmission rates, and patient/staff satisfaction. It also discusses prehabilitation, perioperative fluid management, and creating an optimal postoperative ward environment to enhance recovery.
Self-Expandable Metal Stents for the Management of Gastric Outlet Obstruction...JohnJulie1
Gastric outlet obstruction is commonly considered as advanced malignancies of the stomach, duodenum, pancreas, hepatobiliary, and ampullary regions. Surgical bypass and chemotherapy are the common treatment modalities for gastric obstruction. This study was done to determine the outcomes of self-expandable metal stents in patients with gastric outlet obstruction.
Self-Expandable Metal Stents for the Management of Gastric Outlet Obstruction...JapaneseJournalofGas
Gastric outlet obstruction is commonly considered as advanced malignancies of the stomach, duodenum, pancreas, hepatobiliary, and ampullary regions. Surgical bypass and chemotherapy are the common treatment modalities for gastric obstruction. This study was done to determine the outcomes of self-expandable metal stents in patients with gastric outlet obstruction.
A hospital implemented a fast track colorectal surgery program to reduce patients' length of stay and improve recovery. The program utilized evidence-based practices like pre-operative education, early mobilization, and optimized pain relief. For 24 patients, the median length of stay decreased from 10 to 6 days with no adverse events. A patient satisfaction survey found high approval of the fast track approach. The program was expanded to involve more surgeons and showed potential to reduce hospital bed usage.
Information about Gerd surgical management by Dr Dhaval Mangukiya.
Details of both sides of Gerd, Introduction, Surgical Anatomy, Hiatus Hernia, Esophageal dearance, Investigation etc.
http://www.youtube.com/c/DrDhavalMangukiyaGastrosurgeonSurat
https://gastrosurgerysurat.blogspot.com/
https://drdhavalmangukiya.com/
Gastroesophageal Reflux Disease Pathophysiology and TreatmentGeorge S. Ferzli
This document discusses gastroesophageal reflux disease (GERD), including its pathophysiology, symptoms, diagnosis, and treatment options. It provides details on the medical and surgical management of GERD, highlighting the importance of a thorough pre-operative workup including pH testing, manometry, and other diagnostic evaluations to determine the appropriate treatment and ensure good postoperative outcomes. Both medical therapies like proton pump inhibitors and surgical procedures like Nissen fundoplication are discussed as options for treating GERD, with surgery reserved for cases that are refractory to medical management or that involve complications.
FT SURGERY IN SPAIN: ON THE WAY TO IMPLEMENTATION?fast.track
1. The document discusses the implementation of a fast-track surgery (FTS) protocol in 11 Spanish hospitals for colorectal surgery patients.
2. An initial retrospective study of 240 patients found a 37% morbidity rate and average 13-day hospital stay.
3. A prospective study of 234 patients following the FTS protocol found lower 28% morbidity, 7-day average stay, and fewer re-admissions.
4. Compliance with individual FTS protocol elements varied, with an average of 8.4 of 14 elements per patient. Higher compliance was associated with better outcomes.
This patient underwent pancreaticoduodenectomy (PPPD) for pancreatic cancer and experienced a postoperative pancreatic fistula (POPF). On postoperative day 14, the abdominal drain output became blood tinged. Selective angiography revealed a pseudoaneurysm of the gastroduodenal artery (GDA), which was treated with successful embolization. Management of postoperative hemorrhage depends on whether it occurs early (<24 hours) or delayed (1-3 weeks) after surgery. Endoscopy or interventional radiology are options for stable patients, while reoperation may be necessary for unstable patients.
Utilizing ERAS to improve diet advancement post opGastrodiet
Early feeding after surgery, including clear liquids and solid foods within 24 hours, provides nutritional benefits without increasing complications compared to traditional practices of withholding food until bowel function resumes. A meta-analysis of 15 studies found early feeding reduced total postoperative complications and length of stay without increasing mortality, anastomotic leaks, or time to flatus. Recommendations are provided for diet advancement tailored to specific surgeries and conditions. Close collaboration with surgical teams is important to standardize practices and provide guidance on appropriate diets.
Incisional and excisional biopsies involve removing part or all of a mass to establish a diagnosis. Complications can include pain, infection, bleeding, and numbness. Pancreaticojejunostomy is performed by opening the pancreatic duct and attaching the jejunum to provide drainage for intractable chronic pancreatitis pain. Preoperative evaluation and optimization of medical conditions is important. Risks include bleeding, infection, leak, obstruction, and recurrence. Informed consent discusses the procedures and potential complications.
Similar to Enhanced Recovery After Surgery protocol for gastric cancer (20)
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
3. Introduction
● ERAS is a multidisciplinary protocol of care with aim of maintaining normal
physiology and hence facilitating post-op recovery
● Routinely used in colorectal and pancreatic cancer surgeries
○ Significantly reducing surgical morbidity & Mortality Rate, duration of hospital stay, cost of
hospitalization and improving post-op recovery
● Despite its clinical benefits, the implementation has been slow in gastric
cancer surgeries
○ Reasons being among others; lack of convincing data and limitations in institutional
experience
17. ERAS-GC introduced in our hospital
Table1. ERAS perioperative protocol for patients undergoing gastrectomy implemented at Miri Hospital, October
2021
Preop
day
Day of Op
(Day 0)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Education &
Planning
Education about
ERAS
Operative risk
assessment
Consider MIS
for appropriate
cases
Pain Control Epidural PCA or
Paravertebral
IV paracetamol
Diclofenac PR if
required
Remove
epidural/
paraverte
bral for
DG
Oral
analgesia
for DG
Remove
epidural/
paraverte
bral for
TG
Oral
analgesia
for TG
Antibiotics,
Antiemetics & DVT
prophylaxis(1,2)
IV antibiotics for
24 hours
postoperatively
Antiembolic
stockings
Routine
antiemetics
Add LMWH
injection
18. Table1. ERAS perioperative protocol for patients undergoing gastrectomy implemented at Miri Hospital, October
2021
Preop
day
Day of Op
(Day 0)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Exercise(3) Supported to lie
upright in bed
Sit out in a chair
(In ward
depending on
time)
Leg movements
in bed
Breathing
exercises using a
spirometer
Sit out in chair
Support
patient to
mobilise 4
times per day
Other exercise
as per Day 0
NG Tube In place,
removed
immediately after
surgery
Abdominal Drain No drain for DG
1 or 2 drains
Consider
removal
Urinary Catheter In place Consider Consider
ERAS-GC introduced in our hospital
19. Table1. ERAS perioperative protocol for patients undergoing gastrectomy implemented at Miri Hospital, October
2021
Preop
day
Day of Op
(Day 0)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
IV Fluids Fluid restriction
(1-2L)
Fluid
restriction(2L)
Consider
stopping
for DG
Consider
stopping
for TG
Eating and
Drinking(3)
Normal meal
allowed until 6
hours before
surgery and
carbohydrate
drink until 2
hours before
surgery
No bowel
preparation
NPO Sips of water
for DG
NPO for TG
Clear
liquids as
tolerated
for DG
Sips of
water for
TG
Advance
to soft
blended
diet for
DG
Clear
liquids as
tolerated
for TG
Continue
Clear
liquids as
tolerated
for TG
Advance
to soft
blended
diet for
TG
Wound Care Surgical
wounds
checked &
dressing
changed if
necessary
Leave
surgical
wound
undressed,
if dry and
healing
well
Investigations Monitor labs Monitor labs Monitor
labs
Monitor
labs
Check
discharge
Monitor
labs
Monitor
labs
Check
discharge
ERAS-GC introduced in our hospital
20. Table1. ERAS perioperative protocol for patients undergoing gastrectomy implemented at Miri Hospital, October
2021
Preop
day
Day of Op
(Day 0)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Investigations Monitor labs Monitor labs Monitor
labs
Monitor
labs
Check
discharge
criteria for
DG
Monitor
labs
Monitor
labs
Check
discharge
criteria for
TG
Discharge criteria(4) ● Adequate pain control : patient should be able to tolerate pain without IV analgesics or with oral analgesic only (measured by
VAS pain score < or = 4 )
● Ability to mobilise and self-care: patient should be able to sit up, walk and perform activities of daily living (eg, go to the toilet,
dress, shower, etc)
● Tolerance of oral intake: patient should be able to tolerate given meals without adverse GI symptoms and not require IV
infusion to maintain hydration
● No abnormal physical signs or laboratory test: Pulse, blood pressure, respiratory rate and body temperature should be
stable and consistent with preoperative levels. White blood cell count, serum hemoglobin, and other blood chemistry should be
stable within acceptable levels
MIS = minimally invasive surgery; DG = distal gastrectomy; TG = total gastrectomy; PCA = patient controlled anesthesia with IV narcotic; DVT = deep vein
thrombosis, LMWH = low molecular weight heparin; GI = gastrointestinal; NPO = nil per os; labs = complete blood count, urea, creatinine & electrolytes; VAS =
visual analog scale.
ERAS-GC introduced in our hospital
22. Cases presentation
Patient under ERAS protocol Patient under TRADITIONAL protocol
Hx 52 y.o F on background of hypothyroidism, ℅
epigastric pain + repeated vomiting for 4 mo.
exacerbated by food
● UGI: gastric antral tumor with GOO
● CT: features highly suggestive of gastric
antrum neoplastic mass
● Bx: diffuse gastric carcinoma with signet ring
differentiation
● Sx: Distal gastrectomy
57 y.o F ℅ epigastric pain for 5 mo. + weight
loss, underwent 4 sessions of chemo.
● UGI: gastric body fungating mass
● CT: fungating gastric neoplasia at lesser
curvature, 4 cm distal to GEJ
● Bx: poorly differentiated carcinoma with
signet ring cell differentiation
● Sx: Total gastrectomy
PreOp Normal meal allowed 6 hrs bfr surgery +
carbohydrate drink until 2 hrs bfr surgery
No solid foods at dinner + no liquids 12 hrs bfr
surgery;
23. Cases presentation
Patient under ERAS protocol Patient under TRADITIONAL protocol
Intra -
op
Open access
4L crystalloids, 500ml colloid, 3FFPs, 2PRBCs
3 intra-abdominal drains
Epidural insertion
Removal of NGT on table
Open access
4L crystalloids, 500ml colloid, 4FFPs, 2PRBCs
3 intra-abdominal drains
Epidural insertion
Removal of NGT on table
Post -
op
No complication
Duration of urinary catheter: 2 days
Duration to peristalsis: 2 days
Duration to oral intake: 1 day
Duration to 1st mobilisation: 1 day
Duration of epidural: 1 day
Duration of hospital stay: 8 days
Admission in ICU for respiratory acidosis (3
days)
Other complications: moderate wound infection
Duration of urinary catheter: 4 days
Duration to peristalsis: 2 days
Duration to oral intake: 5 days
Duration to 1st mobilisation: 2 days
Duration of epidural: 2 days
Duration of hospital stay: 12 days
24. References
● Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008
Aug;248(2):189-98.
● Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and
mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar
1;136(5):E359-86.
● Tanaka, R., Lee, SW., Kawai, M. et al. Protocol for enhanced recovery after surgery improves short-term outcomes for
patients with gastric cancer: a randomized clinical trial. Gastric Cancer 20, 861–871 (2017).
● Jeong O, Kim H. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative
Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. J Gastric Cancer. 2019 Mar 1;19.
● Kang SH, Lee Y, Min S-H, Park YS, Ahn S-H, Park DJ, et al. Multimodal Enhanced Recovery After Surgery (ERAS)
Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for
Gastric Cancer: A Prospective, Randomized, Clinical Trial. Ann Surg Oncol. 2018 Oct 1;25(11):3231–8.
● Ford SJ, Adams D, Dudnikov S, Peyser P, Rahamim J, Wheatley TJ, et al. The implementation and effectiveness of
an enhanced recovery programme after oesophago-gastrectomy: A prospective cohort study. Int J Surg. 2014 Apr
1;12(4):320–4.
● Jeong O, Ryu SY, Park YK. Postoperative Functional Recovery After Gastrectomy in Patients Undergoing Enhanced
Recovery After Surgery. Medicine (Baltimore). 2016 Apr 8;95(14):e3140.
Editor's Notes
1. Jeong O, Kim H. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. J Gastric Cancer. 2019 Mar 1;19.
2. Kang SH, Lee Y, Min S-H, Park YS, Ahn S-H, Park DJ, et al. Multimodal Enhanced Recovery After Surgery (ERAS) Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Cancer: A Prospective, Randomized, Clinical Trial. Ann Surg Oncol. 2018 Oct 1;25(11):3231–8.
3. Ford SJ, Adams D, Dudnikov S, Peyser P, Rahamim J, Wheatley TJ, et al. The implementation and effectiveness of an enhanced recovery programme after oesophago-gastrectomy: A prospective cohort study. Int J Surg. 2014 Apr 1;12(4):320–4.
4. Jeong O, Ryu SY, Park YK. Postoperative Functional Recovery After Gastrectomy in Patients Undergoing Enhanced Recovery After Surgery. Medicine (Baltimore). 2016 Apr 8;95(14):e3140.
1. Jeong O, Kim H. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. J Gastric Cancer. 2019 Mar 1;19.
2. Kang SH, Lee Y, Min S-H, Park YS, Ahn S-H, Park DJ, et al. Multimodal Enhanced Recovery After Surgery (ERAS) Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Cancer: A Prospective, Randomized, Clinical Trial. Ann Surg Oncol. 2018 Oct 1;25(11):3231–8.
3. Ford SJ, Adams D, Dudnikov S, Peyser P, Rahamim J, Wheatley TJ, et al. The implementation and effectiveness of an enhanced recovery programme after oesophago-gastrectomy: A prospective cohort study. Int J Surg. 2014 Apr 1;12(4):320–4.
4. Jeong O, Ryu SY, Park YK. Postoperative Functional Recovery After Gastrectomy in Patients Undergoing Enhanced Recovery After Surgery. Medicine (Baltimore). 2016 Apr 8;95(14):e3140.
1. Jeong O, Kim H. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. J Gastric Cancer. 2019 Mar 1;19.
2. Kang SH, Lee Y, Min S-H, Park YS, Ahn S-H, Park DJ, et al. Multimodal Enhanced Recovery After Surgery (ERAS) Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Cancer: A Prospective, Randomized, Clinical Trial. Ann Surg Oncol. 2018 Oct 1;25(11):3231–8.
3. Ford SJ, Adams D, Dudnikov S, Peyser P, Rahamim J, Wheatley TJ, et al. The implementation and effectiveness of an enhanced recovery programme after oesophago-gastrectomy: A prospective cohort study. Int J Surg. 2014 Apr 1;12(4):320–4.
4. Jeong O, Ryu SY, Park YK. Postoperative Functional Recovery After Gastrectomy in Patients Undergoing Enhanced Recovery After Surgery. Medicine (Baltimore). 2016 Apr 8;95(14):e3140.
1. Jeong O, Kim H. Implementation of Enhanced Recovery after Surgery (ERAS) Program in Perioperative Management of Gastric Cancer Surgery: a Nationwide Survey in Korea. J Gastric Cancer. 2019 Mar 1;19.
2. Kang SH, Lee Y, Min S-H, Park YS, Ahn S-H, Park DJ, et al. Multimodal Enhanced Recovery After Surgery (ERAS) Program is the Optimal Perioperative Care in Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Cancer: A Prospective, Randomized, Clinical Trial. Ann Surg Oncol. 2018 Oct 1;25(11):3231–8.
3. Ford SJ, Adams D, Dudnikov S, Peyser P, Rahamim J, Wheatley TJ, et al. The implementation and effectiveness of an enhanced recovery programme after oesophago-gastrectomy: A prospective cohort study. Int J Surg. 2014 Apr 1;12(4):320–4.
4. Jeong O, Ryu SY, Park YK. Postoperative Functional Recovery After Gastrectomy in Patients Undergoing Enhanced Recovery After Surgery. Medicine (Baltimore). 2016 Apr 8;95(14):e3140.